Charles River - JP Morgan Conference Presentation
Multiple strategies to strengthen portfolio and enhance value
for our clients and shareholders
Disciplined M&A
Strategic Partnerships
Venture Capital
Relationships
M&A remains top, long-term priority for
disciplined capital deployment and
enhances growth strategy
Invested >$4.5B in >25 acquisitions
since 2012
Focused on enhancing breadth of
scientific capabilities, expanding global
scale, and maintaining leadership in
advanced and emerging therapies
Partnerships and licensing
arrangements add innovative
capabilities and cutting-edge
technologies with limited upfront risk
19 active partnerships currently
with >$110M invested to-date (1)
•
Highlights include:
Valo Health - Discovery Al
SAMDI Tech - Label-free high-throughput
screening solutions
Cypre - 3D tumor modeling
PathoQuest - NGS sequencing
Innovative strategy to establish CRL as
a preferred partner to a large group of
emerging, VC-backed biotech
companies and create value
~10% of annual revenue comes from
VC portfolio companies(2)
Nearly 30% avg. annual return on VC
relationships (investments and
revenue)(3)
(1)
Charles River - JP Morgan Conference Presentation (2)
(3)
Amount invested in strategic partnerships excludes purchase price to acquire Distributed Bio.
VC revenue includes VC firms with which we have invested, those which we have a strategic relationship, and other revenue from VC portfolio companies with which we have no formal relationship.
Return calculation as of Oct. 2022 includes VC investment gains and operating cash flow from revenue generated from VC funds in which we have invested (both net of tax). It does not include revenue generated from VC funds in which we have not invested.
21View entire presentation